 Rhythm Pharmaceuticals, Inc. NASDAQ: RYTM shares are trading higher after the French National Agency for Medicines and Health Products Safety and Haute Autorité de santé granted pre-marketing authorization AP1 for IMCIVREE for patients with genetically-confirmed Bardet-Biedl. 